Topamax
page
1
of
1
J&J, Lilly drugs found among best for manic episodes
Aug 17, 2011 16:19 EDT
LONDON (Reuters) - Antipsychotics are far more effective than mood stabilizers in tackling acute manic episodes, researchers found, and Eli Lilly's Zyprexa, Johnson & Johnson's Risperdal and generic haloperidol outperform the rest.
J&J, Lilly drugs found among best for manic episodes
Aug 16, 2011 19:15 EDT
LONDON (Reuters) - Antipsychotics are far more effective than mood stabilizers in tackling acute manic episodes, researchers found, and Eli Lilly's Zyprexa, Johnson & Johnson's Risperdal and generic haloperidol outperform the rest.
J&J recalls 57,000 bottles of epilepsy drug
Apr 14, 2011 12:22 EDT
NEW YORK (Reuters) - Johnson & Johnson said on Thursday it is recalling about 57,000 bottles of its Topamax epilepsy drug after reports of a foul odor, the latest in a string of recalls by the company.
J&J recalls 57,000 bottles of epilepsy drug
Apr 14, 2011 09:19 EDT
NEW YORK (Reuters) - Johnson & Johnson said on Thursday it is recalling about 57,000 bottles of its Topamax epilepsy drug after reports of a foul odor, the latest in a string of recalls by the company.
Two-drug obesity treatment effective: study
Apr 10, 2011 20:39 EDT
A new treatment for obesity that combines two existing drugs resulted in twice as much weight loss as the only approved long-term anti-obesity medication, according to a study released Monday.
Some kids' belly pain could be a migraine
Apr 01, 2011 16:22 EDT
NEW YORK (Reuters Health) - If your child suffers from mysterious abdominal pain, it may be a variety of migraine, according to a new study.
FDA: migraine drug ups risk for oral birth defects
Mar 04, 2011 18:15 EST
WASHINGTON (Reuters) - An epilepsy drug also used to help prevent migraines can increase the risk for oral birth defects in babies born to women taking the medication, U.S. health officials said on Friday.
FDA: migraine drug ups risk for oral birth defects
Mar 04, 2011 14:20 EST
WASHINGTON (Reuters) - An epilepsy drug also used to help prevent migraines can increase the risk for oral birth defects in babies born to women taking the medication, health officials said on Friday.
FDA: migraine drug ups risk for oral birth defects
Mar 04, 2011 12:42 EST
WASHINGTON (Reuters) - An epilepsy drug also used to help prevent migraines can increase the risk for oral birth defects in babies born to women taking the medication, health officials said on Friday.
Infertility more common in women with epilepsy
Oct 12, 2010 10:28 EDT
NEW YORK (Reuters Health) - Women with epilepsy may have a higher-than-average risk of fertility problems, particularly those on multiple anti-seizure drugs, a study published Monday suggests.
Weight loss drug shows promise in clinical trial
Sep 21, 2010 13:31 EDT
LOS ANGELES (Reuters) - An experimental weight loss drug helped obese people lose more than 10 percent of their weight after two years in a clinical trial, but safety details were scant for the drug made by Vivus Inc, which in July was turned down by a panel of U.S. experts.
FDA panel favors Glaxo epilepsy drug
Aug 11, 2010 15:45 EDT
FDA panel of advisers backs GlaxoSmithKline seizure drug, despite side effects. Federal health advisers have ruled that GlaxoSmithKline's epilepsy drug Potiga effectively controls seizures.
FDA panel favors Glaxo epilepsy drug
Aug 11, 2010 15:45 EDT
Federal health advisers have ruled that GlaxoSmithKline's epilepsy drug Potiga effectively controls seizures.
Suicide risk no higher with epilepsy drugs
Aug 04, 2010 17:01 EDT
BOSTON (Reuters) - Some seizure drugs may not raise the risk of suicide for patients with epilepsy as feared, but they more than double the risk for people with depression, researchers reported on Wednesday.
Only some epilepsy drugs may raise suicide risk
Jul 26, 2010 17:26 EDT
NEW YORK (Reuters Health) - While all epilepsy drugs carry a warning about an increased risk of suicidal behavior, it may only be certain newer medications that are connected to the hazard, a study published Monday suggests.
FDA panel rejects experimental weight loss pill
Jul 15, 2010 18:22 EDT
A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.
FDA panel rejects experimental weight loss pill
Jul 15, 2010 18:21 EDT
FDA panel says side effects of Vivus weight loss drug outweigh benefits. A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.
FDA panel rejects experimental weight loss pill
Jul 15, 2010 17:40 EDT
FDA panel says side effects of Vivus weight loss drug outweigh benefits. A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.
FDA to review first of 3 new weight loss drugs
Jul 12, 2010 16:51 EDT
FDA to evaluate obesity drug that would be the first new prescription treatment in a decade. Dieters, doctors and investors get their first extensive look at the first of a trio of new weight loss drugs this week. The hope is that the new drugs can succeed where many others have failed: delivering significant weight loss without risky side effects.
New obesity pills try to shed past problems
Jul 08, 2010 15:06 EDT
WASHINGTON (Reuters) - The first of three new fat-fighting pills faces public scrutiny by U.S. regulatory advisers next week, as small biotechs target the growing number of obese Americans despite a checkered past for weight-loss drugs.
Facts from the Wikipedia page:
 | |
 | |
| Systematic (IUPAC) name | |
|---|---|
| 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate | |
| Identifiers | |
| CAS number | 97240-79-4 |
| ATC code | N03AX11 |
| PubChem | 5284627 |
| DrugBank | APRD00237 |
| ChemSpider | 4447672 |
| Chemical data | |
| Formula | C12H21NO8S |
| Mol. mass | 339.363 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | 80% |
| Metabolism | 30% hepatic, 70% is excreted unchanged |
| Half life | 19 to 23 hours |
| Excretion | 70% renal (in urine) in unchanged form |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
 (what is this?) (verify) | |
